Literature DB >> 7614470

2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.

C U Lambe1, D R Averett, M T Paff, J E Reardon, J G Wilson, T A Krenitsky.   

Abstract

Earlier studies have shown guanine arabinoside (ara-G) is an effective agent against growth of T-cell lines and freshly isolated human T-leukemic cells. However, poor water solubility of ara-G limits clinical use. 2-Amino-6-methoxypurine arabinoside (506U) is a water-soluble prodrug converted to ara-G by adenosine deaminase. 506U is not a substrate for deoxycytidine kinase, adenosine kinase, or purine nucleoside phosphorylase and is phosphorylated by mitochondrial deoxyguanosine kinase at a rate 4% that of ara-G phosphorylation. Mitochondrial DNA polymerase was the least sensitive to ara-GTP inhibition of the five human DNA polymerases tested. [3H]506U was anabolized to ara-G 5'-phosphates in CEM cells but not to phosphorylated metabolites of 506U. 506U was selective for transformed T over B cells and also inhibited growth in two of three monocytic lines tested. 506U given i.v. to cynomolgus monkeys was rapidly converted to ara-G; the ara-G had a half-life of approximately 2 h. 506U had in vivo dose-dependent efficacy against human T-cell tumors in immunodeficient mice. A Phase 1 trial of 506U against refractory hematological malignancies is now in progress at two study sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614470

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.

Authors:  Jelena Levi; Tina Lam; Samuel R Goth; Shahriar Yaghoubi; Jennifer Bates; Gang Ren; Salma Jivan; Tony L Huynh; Joseph E Blecha; Roli Khattri; Karl F Schmidt; Dominique Jennings; Henry VanBrocklin
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

Review 2.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 3.  Relapsed T Cell ALL: Current Approaches and New Directions.

Authors:  Christine M McMahon; Selina M Luger
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

Review 4.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

5.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

6.  Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection.

Authors:  Wonsuk Chang; Donghui Bao; Byoung-Kwon Chun; Devan Naduthambi; Dhanapalan Nagarathnam; Suguna Rachakonda; P Ganapati Reddy; Bruce S Ross; Hai-Ren Zhang; Shalini Bansal; Christine L Espiritu; Meg Keilman; Angela M Lam; Congrong Niu; Holly Micolochick Steuer; Phillip A Furman; Michael J Otto; Michael J Sofia
Journal:  ACS Med Chem Lett       Date:  2010-12-17       Impact factor: 4.345

Review 7.  Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Tapan M Kadia; Varsha Gandhi
Journal:  Expert Rev Hematol       Date:  2016-12-08       Impact factor: 2.929

Review 8.  Nelarabine.

Authors:  Mark Sanford; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Authors:  Daniel J DeAngelo; Daohai Yu; Jeffrey L Johnson; Steven E Coutre; Richard M Stone; Alison T Stopeck; Jon P Gockerman; Beverly S Mitchell; Frederick R Appelbaum; Richard A Larson
Journal:  Blood       Date:  2007-03-07       Impact factor: 22.113

10.  Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Authors:  Todd M Cooper
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.